(Q38117077)

29 August 2017

title

Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia (English)

1 reference

29 August 2017

0 references

James E Frampton

1

1 reference

29 August 2017

publication date

1 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

73

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

1067-1094

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0075-6

29 August 2017

exact match

0 references

cites work

Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Ceftaroline fosamil: a new broad-spectrum cephalosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007-08).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro activity of ceftaroline against clinical isolates of Streptococcus pneumoniae recovered in 43 U.S. medical centers during 2010-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Community-associated meticillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Effect of ceftaroline on normal human intestinal microflora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

General principles of antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Clinical impact of antibiotic-resistant Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

The problem of complicated skin and skin structure infections: the need for new agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

New treatments for methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. a

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0075-6

New antimicrobial agents for methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

12 December 2020

AmpC induction by ceftaroline

1 reference

12 December 2020

Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics

1 reference

12 December 2020

Postantibiotic effect of ceftaroline against gram-positive organisms

1 reference

12 December 2020

Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus

1 reference

12 December 2020

Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model

1 reference

12 December 2020

Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia

1 reference

12 December 2020

Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials

1 reference

12 December 2020

Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study

1 reference

12 December 2020

Penicillin-binding proteins 2x and 2b as primary PBP targets in Streptococcus pneumoniae

1 reference

12 December 2020

Guidelines for the management of adult lower respiratory tract infections - Summary

1 reference

12 December 2020

10.1007/S40265-013-0075-6

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1007406866

0 references

1 reference